Genomics and proteomics of retinopathy of prematurity: DNA-based prevention and treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study.Ophthalmology · 2011
   Trial
2. Essential Role of Multi-Omics Approaches in the Study of Retinal Vascular Diseases.Cells · 2022
   Review
3. Aberrant cell adhesion molecule expression in human bronchopulmonary sequestration and congenital cystic adenomatoid malformation.American journal of physiology. Lung cellular and molecular physiology · 2009
   Article

Corrections and comments

• Comment on
  Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies.2007

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as